Discontinuing PSA Screening: Perspectives From PCPs | News Brief

Age and life expectancy appear to be considered often by primary care providers (PCPs) when considering the discontinuation of PSA screening. Nearly 60% of PCPs considered both age and life expectancy in their decision, while 12.2% did not consider either factor. Patient expectations and time constraints were reported by 74.4% and 66.4% of PCPs, respectively, as barriers to discontinuing PSA screening.

Abstract: Cancer, November 15, 2012.


From our CME partner, AKH Inc.

CME: On the Spot Oncology
CME Credit: .25 hour activities

While several aspects of therapy for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) have remained unchanged for several decades, new therapeutic options have emerged within the past 5 years, particularly targeted agents. These agents represent a new era for treatment of GEP-NETs, but also create a key area of educational need, as the new data challenge the current paradigm of patient treatment. These activities review the novel treatment choices for improving care in patients diagnosed with GEP-NETs.

eMedia - Primary Care




Physician's Weekly for Current Medical News, Events & Issues